In committee
Lowering Drug Costs for American Families Act
This bill expands federal prescription drug price negotiations from 20 to 50 medications and extends those discounted prices to people with private and job-based health insurance. Starting in 2027, most private health plans must cap an individual's out-of-pocket prescription drug spending at $2,000 per year and limit insulin copays to no more than $35 per month without requiring a deductible. In addition, the legislation requires drug manufacturers to pay rebates if they increase commercial drug prices faster than inflation and requires federal negotiators to factor in prices paid in six peer countries starting in 2028.
People affected—The bill applies broadly to participants, beneficiaries, and enrollees in Medicare, group health plans, and individual health insurance markets nationwide, but does not provide a specific population count.
Fiscal magnitude—no CBO estimate published
Reach85provisional · pending reviewrigor: heuristic llm
What this bill touches.
Government role in coverage+40Pharmaceutical pricing+70
Who it helps · who it burdens.
Who it helps
- Enrollees in private commercial and group health plansReceive lower out-of-pocket prescription drug costs through a $2,000 annual spending cap (starting in 2027), a $35 monthly cap on selected insulin products with no deductible, and access to Medicare-negotiated drug prices in participating plans.
- Medicare beneficiariesGain access to up to 50 negotiated drug prices annually instead of 20, with federal negotiations incorporating international reference pricing from six countries starting in 2028.
- Individuals under age 21Gain access to dedicated child-only health plan options from issuers that offer tiered health coverage in individual and group markets.
Who it burdens
- Prescription drug manufacturersMust pay mandatory inflation rebates to the federal government on prescription drugs sold in the commercial market when price increases outpace inflation, and face expanded price negotiation on up to 50 drugs per year benchmarked against international prices.
- Group health plans and health insurance issuersMust limit annual prescription drug out-of-pocket cost-sharing to $2,000, cap insulin copays at $35 per month with zero deductible, offer child-only plans, and either provide Medicare-negotiated drug prices to enrollees or formally opt out and publish disclosure notices.
Who backs it
- Prescription drug manufacturersPay mandatory inflation rebates on commercial sales of Part B and Part D drugs if prices increase faster than inflation.